Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross-sectional study by Janette Furuzawa-Carballeda et al.
RESEARCH ARTICLE Open Access
Peripheral regulatory cells immunophenotyping in
Primary Sjögren’s Syndrome: a cross-sectional
study
Janette Furuzawa-Carballeda†, Gabriela Hernández-Molina†, Guadalupe Lima, Yahaira Rivera-Vicencio,
Karen Férez-Blando and Luis Llorente*
Abstract
Introduction: IL-10–producing B cells, Foxp3-expressing T cells (Tregs) and the IDO-expressing dendritic cells (pDC)
are able to modulate inflammatory processes, to induce immunological tolerance and, in turn, to inhibit the
pathogenesis of autoimmune disease.
The aim of the study was to characterize and to enumerate peripheral IL-10–producing B cells, Tregs and pDCregs
in primary Sjögren’s Syndrome (pSS) patients in regard of their clinical and serologic activity.
Methods: Fifty pSS patients and 25 healthy individuals were included in the study. CD19+–expressing peripheral B
lymphocytes were purified by positive selection. CD19+/CD24hi/CD38hi/IL-10–producing B cells, CD4+/CD25hi/Foxp3+
and CD8+/CD28-/Foxp3+ Tregs, as well as CCR6+/CD123+/IDO+ DCs, were quantitated by flow cytometry.
Results: Immature/transitional circulating IgA+ IL-10–producing B cells had higher levels in pSS patients versus control
group, whereas CD19+/CD38hi/IgG+/IL-10+ cells had lower percentage versus control. Indeed CD19+/CD24hi/CD38hi/
CD5+/IL-10+, CD19+/CD24hi/CD38hi/CD10+/IL-10+, CD19+/CD24hi/CD38hi/CD20+/IL-10+, CD19+/CD24hi/CD38hi/CD27-/IL-
10+, and CD19+/CD24hi/CD38hi/CXCR7+/IL-10+ cells had higher frequency in clinical inactive pSS patients when
compared with control group. Remarkably, only percentages of CD19+/CD24hi/CD38hi/CD10+/IL-10+ and CD19+/
CD24hi/CD38hi/CD27-/IL-10+ subsets were increased in pSS serologic inactive versus control group (P < 0.05). The
percentage of IDO-expressing pDC cells was higher in pSS patients regardless of their clinical or serologic activity. There
were no statistically significant differences in the percentage of CD4+/CD25hi/Foxp3+ Tregs between patient groups
versus controls. Nonetheless, a decrease in the frequency of CD8+/CD28-/Foxp3+ Tregs was found in inactive pSS
patients versus controls (P < 0.05).
Conclusions: The findings of this exploratory study show that clinical inactive pSS patients have an increased
frequency of IL-10–producing B cells and IDO-expressing pDC cells.
Introduction
Progress in clarifying cellular, molecular and biochemical
processes that regulate immune response provides increas-
ingly acceptable enlightenment for the normal status of
tolerance to self-antigens that guards most humans from
Ehrlich’s imagined horror, autotoxicus [1]. Emerging data
on the IL-10-producing B-cell subset provide fertile
ground for resolving some perplexing immunological
paradoxes. The immunoregulatory role of B cells in auto-
immune disease was initially characterized in B cell-
deficient mice immunized with a myelin basic protein
peptide in complete Freund’s adjuvant, where mice
develop exacerbated encephalomyelitis compared to con-
trols [2]. This Breg subset differentiates in a chronic
inflammatory environment, expresses high levels of CD1d,
produces IL-10, and suppresses the progression of intest-
inal inflammation by directly downregulating inflamma-
tory cascades associated with IL-1b and signal transducer
and activator of transcription 3 (STAT3) activation [3,4].
Lately, it has been described as a CD19+CD24hiCD38hi
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immature/transitional B-cell subset that suppresses
the differentiation of T helper (Th)1 cells in an IL-10-
dependent, but TGF-b-independent manner, which
requires CD80/CD86 interactions with target CD4+
T cells. Remarkably, it has been shown that in patients
with systemic lupus erythematosus (SLE), the CD19+
CD24hiCD38hi B subset produces less IL-10 in
response to CD40 stimulation and is unable to inhibit
Th responses, suggesting that altered cellular function
of the subpopulation in SLE may impact the immune
effector responses in this autoimmune disease [4].
Furthermore, in renal transplant patients, increased
frequency of CD19+CD24hiCD38hi has been associated
with operational tolerance [5-8]. In addition, these IL-
10-producing B cells favor the differentiation and
maintenance of regulatory Foxp3-expressing T cells
(Tregs) and may control organ-specific inflammation
[3,4,9].
On the other hand, the catabolism of tryptophan, by the
enzyme indoleamine 2,3-dioxygenase (IDO) expressed in
plasmacytoid dendritic cells (pDCs), generates kynure-
nines, 3-hydroxyanthranilic, and quinolic acids, molecules
with the ability to induce Th1 over Th2-cell apoptosis and
to exert cytotoxic action on T, B and natural killer (NK)
cells, but not on dendritic cells (DCs) themselves [10,11].
IDO has a selective sensitivity for Th1 over Th2 cells to
tryptophan metabolites, suggesting a potential role for
Th2 differentiation [12]. Furthermore, deprivation of tryp-
tophan by IDO halts the proliferation of T cells at mid-G1
phase, which in concert with the pro-apoptotic activity of
kynurenine, leads to diminishing T cell-mediated immune
responses and the subsequent development of immune
tolerance [13-17]. As IL-10-producing B cells, IDO-com-
petent DCs have been shown to induce IL-10-producing
Treg cells (Tr1) and CD4+/CD25hi/Foxp3+ Tregs in vivo,
and Treg-expressed glucocorticoid-induced TNF receptor
(GITR), which in turn, can use IDO+ DCs to expand their
own population in a positive feedback loop [18-20].
Thus, quantitative and functional modifications of IL-10-
producing B cells, Tregs and IDO-producing cells, might
play a role in the pathogenesis and disease activity of auto-
immune systemic disorders, including primary Sjögren’s
syndrome (pSS) [21], an autoimmune exocrinopathy char-
acterized by chronic lymphocytic inflammation of the lacri-
mal and salivary glands resulting in keratoconjunctivitis
sicca and xerostomia. Indeed, there are several features of
systemic disease that may also involve additional organ sys-
tems. Although the glandular destruction has been shown
to be mainly mediated by CD45RO+/CD4+ T lymphocytes,
chronic B cell activation and proliferation seem to play an
intimate role [22]. In this vein, evidence of B cell hyperac-
tivity, including circulating immune complexes, hypergam-
maglobulinemia, and/or autoantibodies, are frequently
found in patients with pSS [22-25]. Moreover, it has been
demonstrated that patients with pSS exhibit disturbed B-
cell subset distribution in their blood [2].
In order to delineate the peripheral cell types with
regulatory properties in patients with pSS, the aim of
this study was to characterize and to enumerate IL-10-
producing B cell subpopulations according to previous
immunophenotyping studies [4,26,27], Foxp3-expressing
CD4+/CD25hi and CD8+/CD28- T cells, and IDO-produ-
cing CCR6+/CD123+ DCs by flow cytometry.
Material and methods
Patients
For this exploratory, observational, cross-sectional study,
we included 50 consecutive pSS patients regularly attend-
ing the Department of Immunology and Rheumatology at
the Instituto Nacional de Ciencias Médicas y Nutrición
Salvador Zubirán, a tertiary care center. Eligible patients
had to fulfill the American-European Consensus Group
criteria for pSS [28], not meet classification criteria for any
other autoimmune disease and not have concomitant lym-
phoma. All patients had a face-to-face interview with one
rheumatologist (GH) using a standardized form, which
included questions about demographic data, use of medi-
cations and symptoms. Patients may or not have been
receiving prednisone or immunosuppressors at the time of
the assessment; however they were not included if conco-
mitant infection was present. Furthermore, disease activity
status was assessed using the European League Against
Rheumatism (EULAR) Sjögren’s syndrome disease activity
index (ESSDAI) [29] and Sjögren’s syndrome disease activ-
ity index (SSDAI) validated scales [30]. Both indexes evalu-
ate glandular (enlarged parotid glands) and extraglandular
features such as fatigue, non-erosive arthritis, skin vasculi-
tis, interstitial lung disease, renal involvement, neurological
involvement, myositis, lymphadenopathy/splenomegaly,
hematological involvement and fever. In addition the ESS-
DAI has a biological domain that evaluates hypocomple-
mentemia, cryoglobulinemia, hypergammaglobulinemia or
high immunoglobulin G (IgG) levels. For the present
study, the patients were allocated to two groups, those
with clinically active disease (n = 17) and those with clini-
cally inactive disease (n = 33). We defined clinically active
disease as the presence of one or more glandular and
extraglandular features recognized by the ESSDAI and
SSDAI with the exception of fatigue. If any manifestation
could be secondary to other concomitant condition
besides SS, the feature was not considered as part of the
activity assessment. Finally patients’ clinical records were
carefully reviewed to collect information about the disease
onset and follow-up. In addition 25 age-matched healthy
donors (HD) were included as controls. HD were also
interviewed to discard any known autoimmune disease,
use of immunosuppressors and prednisone and concur-
rent infections.
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The protocol was approved by the Committee of Medi-
cal Ethics (Reference number 348) and performed in
accordance with the revised Declaration of Helsinki. All
patients gave written informed consent to participate.
Serologic markers
Levels of serum IgG, IgM, IgA, C3 and C4 complement
proteins were determined by immunoturbidimetry,
serum hyperviscosity was assessed with an Ostwald visc-
ometer, and erythrocyte sedimentation rate (ESR) was
determined by the Westergren method at the assess-
ment. Serologic activity was defined as the presence of
one or more of the following features: serum viscosity
>2 AU, elevated IgG (>1,741 mg/dL), IgM (>281 mg/dL),
IgA (>433 mg/dL) or decreased levels of complement C3
(<90 mg/dL) and C4 (<10 mg/dL).
Isolation of peripheral blood mononuclear cells (PBMC)
A sample of venous blood (120 mL) was obtained from
each subject. PBMC were isolated by gradient centrifu-
gation on the Lymphoprep (Axis-Shield PoC AS, Oslo,
Norway).
B-cell purification and cytometric analysis
CD19-mAb-coated microbeads (Miltenyi Biotec, Ber-
gisch Gladbach; Germany) were used to purify blood B
cells by positive selection following the manufacturer’s
instructions. Purity was assessed by fluorescence-acti-
vated cell sorting (FACS) staining for the B- and T-cell
markers. Thus, anti-human CD19-PE and anti-human
CD3-FITC monoclonal antibodies were used. This pro-
cedure normally yielded B-cell preparations which were
>95% CD19+.
Flow cytometry
CD19+ cells were surface stained with several combina-
tions of anti-human fluorochrome-conjugated antibodies
for four-color analysis. CD19+ cells were stained with
5 μL of anti-CD38-PECy5-labeled (clone: HIT2), anti-
CD38-PE-conjugated (clone: HIT2), anti-CD24-FITC-
labeled (clone: ML5), anti-IgG-PECy5-conjugated (clone:
G18-145), anti-IgM-APC-labeled (clone: G20-127), anti-
CD5-APC-conjugated (clone: L17F12), anti-CD10-APC-
labeled (clone: HI10a), anti-CD20-APC-conjugated
(clone: 2H7), anti-CD27-APC-labeled (clone: M-T271),
anti-CXRC4-APC-conjugated (clone: 12G5) (BD Bios-
ciences, San Jose, CA, USA), anti-CXCR7 (polyclonal,
Abcam Inc, Cambridge, MA, USA), anti-rabbit IgG-Cy5-
labeled polyclonal antibody (Abcam Inc,) and anti-IgA-
PE-conjugated (clone: 11-44-2, eBioscience, San Diego,
CA, USA). CD19+ cells were permeabilized with 200 μL
of cytofix/cytoperm solution (BD Biosciences) at 4°C for
20 minutes, then they were stained for intracellular IL-
10 with PE-conjugated-anti-IL-10 (clone: JES3-19F1, BD
Biosciences) or fluorescein isothiocyanate (FITC)-
labeled-anti-IL-10 (clone: BT10, eBioscience). Finally,
CD19+ subsets were analyzed by flow cytometry with a
FACScalibur (BD Biosciences). An electronic gate was
made for CD38hi, IgA+, IgG+, or IgM+ and IL-10+ or for
CD19+/CD38hi/CD24hi, CD5+, CD10+, CD20+, CD27+,
CXCR4+ or CXCR7+ and IL-10+ cells and a total of
50,000 to 100,000 events were recorded for each sample
and analyzed with the CellQuestPro software (BD Bios-
ciences). Results are expressed as the relative percentage
of IL-10-expressing B cells in each gate. As isotype con-
trols, IgG1-FITC/IgG1-PE/CD45-PeCy5 mouse IgG1, k
(BD Tritest™, BD Biosciences) and PE-conjugated-anti
rat-IL-10 IgG (clone: R35-95, BD Biosciences) were used
to set the threshold and gates in the cytometer. We ran
an unstained (autofluorescence control) and permeabi-
lized PBMC sample. Autofluorescence control was com-
pared to single-stained cell-positive controls to confirm
that the stained cells were on scale for each parameter.
CaliBRITE™ 3 beads (BD Biosciences) were used to
adjust instrument settings, set fluorescence compensa-
tion, and check instrument sensitivity.
To determine IDO cell expression, non-B cells (unla-
beled cells obtained from the column while the magneti-
cally labeled CD19+ B cells were retained on the column)
were conjugated with an anti-human CCR6-PE (clone:
11A9) and CD123-PECy5 (clone: 9F5) monoclonal antibo-
dies (BD Biosciences). Cells were permeabilized and
stained with a polyclonal sheep anti-human-IDO (Pierce
Biotechnology, Rockford, IL, USA) and then with FITC-
conjugated-rabbit polyclonal anti-sheep antibody (Chemi-
con, Temecula, CA, USA). The cell subset was analyzed
by flow cytometry. As the control for FITC-labeled rabbit
anti-sheep specificity staining, cells were incubated with
surface antibodies and FITC-conjugated rabbit anti-sheep
in the absence of sheep anti-human IDO antibody. An
electronic gate was made for each of the surface markers
employed. Results are expressed as the relative percentage
of IDO-expressing cells in each gate.
For Tregs, non-CD19+ B cells were labeled with an anti-
human CD4-FITC (clone: RPA-T4) and CD25-PECy5
(clone: M-A251) or CD8a-FITC (clone: HIT-8a) and
CD28-PECy5 (clone: CD28.2) (BD Biosciences). Intracellu-
lar staining was performed with an anti-human Foxp3-PE-
conjugated monoclonal antibody (clone: 259D/C7) (BD
Biosciences). An electronic gate was made for CD4
+/CD25hi cells or CD8+/CD28-. Results are expressed as the
relative percentage of Foxp3-expressing cells in each gate.
The relative percentage of IL-10-producing B cells, pDC
IDO+ and Foxp3+ Treg circulating cells was obtained from
the percentage of CD19+/CD38hi/CD24hi/IL-10+, CCR6+/
CD123hi , CD4+/CD25hi or CD8+/CD28- cells, respectively.
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Statistics
Descriptive statistics were performed and categorical
variables were compared using the X² test or Fisher’s
exact test; for analysis of continuous variables the Stu-
dent t-test was employed. One-way analysis of variance
on ranks using the Dunn method was performed for all
pairwise multiple comparison procedures. Statistical
analysis was done using the SigmaStat11.2 program
(Aspire Software International, Leesburg, VA, USA).
Data were expressed as the median and range, or mean ±
SD/standard error of the mean (SEM). P-values smaller
than or equal to 0.05 were considered significant.
Results
Demographic, clinical and laboratory data
Clinical, demographic and serological variables of
patients are summarized in Table 1 and Figure 1. Of
50 patients with pSS 96% percent were female with a
mean age of 53 ± 12 years, median disease duration of
9.7 years (0.97 to 42.0 years), and median disease activ-
ity score of 0 (0–6) assessed by the SSDAI and 1 (0 to
5) assessed by the ESSDAI. For therapy, 22% were
receiving prednisone and 38% were receiving at least
one immunosuppressor as follows: antimalarial drugs,
11 patients (22%); azathioprine, 6 patients (12%); metho-
trexate, 5 patients (10%); and cyclophosphamide, 2
patients (4%). Seventeen patients (34%) had clinical
activity manifested as parotid enlargement, vasculitis,
arthritis, leukopenia, lymphopenia, pneumonitis and
optic neuritis.
Forty-four percent (27/50) of patients had serological
activity (with or without concomitant clinically active
disease). There was no difference in the use of steroids
or immunosuppressors in patients with and without ser-
ologic activity, no difference in the age of patients with
active or inactive disease (49 versus 55 years, P = 0.07)
and no difference in disease duration (10.9 versus 7.7
years, P = 0.24). However, as expected, patients with
clinically active disease had higher SSDAI and ESSDAI
scores (Table 1) and more frequently received predni-
sone (53% versus 6%, P = 0.001). On the other hand,
patients with clinically active disease more frequently
received immunosuppressors (58% versus 30%), but this
difference was not statistically significant (P = 0.06). The
frequency of medication use was as follows: azathiopr-
ine, 29% versus 3% (P = 0.01); methotrexate, 17% versus
6%; cyclophosphamide, 5% versus 3%, (P = 0.54); and
antimalarial drugs, 35% versus 21% (P = 0.78), among
patients with clinically active and inactive disease,
respectively.
Peripheral IL-10-producing B cells in patients with pSS
To determine the different subtypes of IL-10-producing
B cells, first CD19+/CD38hi/CD24hi/IL-10+ immature/
transitional circulating cells were identified and subse-
quently they were subphenotyped by determining the Ig
expression on their surface (Table 2). Compared with
healthy subjects, the CD19+/CD38hi/CD24hi/IL-10-
producing B-cell subpopulation (0.20 ± 0.02% in healthy
subjects) was greater in pSS patients with clinically inac-
tive disease (0.63 ± 0.06%), with clinically active disease
(0.55 ± 0.05%), with positive serology (0.57 ± 0.07%) and
without serologic activity (0.53 ± 0.07%) (P < 0.05)
(Table 2; Figure 2A). However, no differences were
found in the frequency of circulating CD19+/CD38hi/IL-
10+ B cells among groups of patients (Table 2).
For Ig surface expression, no changes were found in
the CD19+/CD38hi/IgM+/IL-10+ B-cell subpopulation
between patient subgroups (Table 2; Figure 3I). How-
ever, the relative frequency of CD19+/CD38hi/IgG+/IL-
10+ was lower in all pSS subgroups when compared
with the healthy control group (Table 2; Figure 3J). pSS
patients with clinical activity had significantly lower
levels of CD19+/CD38hi/IgG+/IL-10+ compared to those
with clinically inactive disease (38.6 ± 3.7 versus 48.1 ±
2.0%; P < 0.05) (Table 2; Figure 3J). With the exception
of pSS patients with clinically active disease, all pSS sub-
groups had higher frequency of CD19+/CD38hi/IgA+/IL-
10+ B cells compared with the healthy control group
(P < 0.05) (Table 2; Figure 3L). It is important to recall
that the results are expressed as the relative percentage
obtained from CD19+/CD38hi/IL-10+ B cells (Table 2).
The frequency of immature/transitional CD19+/CD38hi/
CD24hi/CD5+/IL-10+ B cells was higher in patients with-
out clinical activity and lower in patients with clinical
activity when compared with the control group (P < 0.05)
(Table 2; Figure 4E). The percentage of CD19+/CD38hi/
CD24hi/CD10+/IL-10+ was higher in pSS patients who had
both clinical and serologic inactivity when compared to
healthy subjects (P < 0.05) (Table 2; Figure 4F). Moreover,
CD19+/CD38hi/CD24hi/CD10+/IL-10+ circulating B cells
were higher in pSS patients with clinically inactive versus
clinically active disease, and in pSS patients without sero-
logic activity versus pSS patients with serologic activity
(P < 0.05) (Table 2; Figure 4F). The percentage of CD19+/
CD38hi/CD24hi/CD20+/IL-10+ was higher in pSS patients
with clinically inactive disease when compared to healthy
subjects, and to pSS patients with clinically active disease
(P < 0.05) (Table 2; Figure 4G).
In addition, a different IL-10 B subset, a non-memory
B cell that could be the human counterpart of mouse
marginal-zone B cells, a CD19+/CD38hi/CD24hi/CD27+
B10 subset was also immunophenotyped. No statistically
significant differences were found in the B10 subset
between pSS patients and the control group (Table 2).
Nonetheless, the percentage of CD19+/CD38hi/CD24hi/
CD27-/IL-10+ cells was increased in pSS patients inde-
pendently of clinical or serologic activity (P < 0.050
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Control, control group of healthy individuals. aP < 0.05: patients with clinically active versus clinically inactive primary Sjögren’s syndrome (pSS); bP < 0.05: patients with serologically active versus serologically
inactive pSS; cP < 0.05: patients with clinically and serologically active versus clinically active but serologically inactive pSS; dP < 0.05: patients with clinically inactive but serologically active versus clinically and

















(Table 2; Figure 4H). The percentage of CD19+/CD38hi/
CD24hi/CXCR4+/IL-10+ cells was similar in pSS patients
and the healthy control group (Table 2; Figure 4I). The
cell frequency of CD19+/CD38hi/CD24hi/CXCR7+/IL-10+
was higher in pSS patients without clinical activity when
compared with pSS patients with clinically active disease
and healthy controls (P < 0.05) (Table 2; Figure 4J). It is
important to note that the results are expressed as the
relative percentage obtained from CD19+/CD38hi/
CD24hi/IL-10+ B cells (Figure 2A, red bars).
Percentage of IDO+ plasmacytoid dendritic cells in
patients with pSS
A subpopulation of plasmacytoid DCs derived from
monocytes expressing CD123hi/CCR6+/IDO+ that are
responsible for mediating the suppression of effector T
cells has recently been described. The frequency of
these cells in peripheral blood was higher in all sub-
groups of patients with pSS when compared with the
control group (P < 0.05) (Table 2; Figure 5I).
Frequency of Foxp3+ regulatory T cells circulating in
patients with pSS
We performed analyses to determine the various subpo-
pulations of lymphocytes that regulate the adaptive
immune response and induce peripheral tolerance of
CD4+/CD25hi/Foxp3+ and CD8+/CD28-/Foxp3+ cell sub-
populations. There were no statistically significant differ-
ences in the frequency of CD4+/CD25hi/Foxp3+ cells
(Table 2; Figure 5J). Nevertheless, a lower percentage of
CD8+/CD28-/Foxp3+ cells was observed in pSS patients
without clinically active disease but with serologic activ-
ity compared with the healthy control group (P < 0.05)
(Table 2; Figure 5K).
Figure 1 Clinical and laboratory data for patients with primary Sjögren’s syndrome (pSS). Results are expressed as median, 10th, 25th, 75th,
and 90th percentiles. *P < 0.05. SSDAI, Sjögren’s syndrome disease activity index; ESSSDAI, European League Against Rheumatism Sjögren’s
syndrome disease activity index; Ig, immunobglobulin; ESR, erythrocyte sedimentation rate.
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Control, control group of healthy individuals. aP < 0.05: patients with clinically active versus clinically inactive primary Sjögren’s syndrome (pSS); bP < 0.05: patients with serologically active versus serologically
inactive pSS; cP < 0.05: patients with clinically and serologically active versus clinically active but serologically inactive pSS; dP < 0.05: patients with clinically inactive but serologically active versus clinically and

















For a long time, pSS was considered a Th1 autoimmune
disease, and this lymphocyte subset has been the protago-
nist of immune damage. Nevertheless, the contemporary
view of pSS considers the B cell population as preponder-
ant in its pathogenesis [22]. Nevertheless, this new
hypothesis does not consider regulatory B cells, probably
due the recent description or the scarce information
about their role in pSS. Recently, however, phenotypic
and functional features of these novel IL-10-producing B
cells have been described, for example, they are potent
suppressors of Th1 cell differentiation (through cell-cell
contact and production of IL-10), are inhibitors of auto-
immune pathogenesis, and importantly, can restore
immune system homeostasis [31]. It is worth mentioning
that regulatory B cells represent only 0.2 to 0.6% of total
B cells, suggesting that its regulatory potential is highly
effective.
The objective of this study was to characterize three sub-
populations of regulatory cells namely, IL-10-producing
B cells, Foxp3-expressing T cells and IDO-expressing DCs
in 50 patients with clinically active or inactive and serologi-
cally active or inactive pSS. Unexpectedly, CD4+/CD25hi/
Foxp3+ regulatory T cells were comparable between all
pSS groups, suggesting that, at least systemically, these
cells are not affected by clinical or serologic pSS activity
and, moreover, do not appear to be an important periph-
eral cell biomarker. Furthermore, in an indirect way, these
data support the hypothesis of the key role B cells play in
disease pathogenesis [22,31,32].
Furthermore, a previous study reported that the num-
ber of infiltrating CD4+/CD25hi/Foxp3+ cells positively
correlated with the minor salivary gland biopsy focus
score and negatively correlated with the prevalence of
these cells in the peripheral blood, suggesting a reverse
regulation in the periphery and the affected tissue. Never-
theless, in patients with advanced histologic lesions, high
percentages of Treg cells were detected in peripheral
blood [33]. According to our data, we also support the
low prevalence of these circulating cells suggesting a
Figure 2 Percentage of circulating cells. (A) IL-10-producing B cells, (B) CCR6+/CD123hi-, (C) CD8+/CD28-- and (D) CD4+/CD25hi-circulating
cells. Results are expressed as mean. *P < 0.05, for comparison of pSS patients with control (CTL) group.
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reverse peripheral regulation and injured tissue. On the
other hand, our work provides evidence for the presence
of another subpopulation of naturally occurring regula-
tory T cells, the CD8+/CD28-/Foxp3+ cell subset. They
were found at lower levels in all pSS patient groups when
compared with the healthy control group, suggesting that
IL-10-producing regulatory CD8+ T cells might be
migrating to the lacrimal and salivary glands, as a result
of their regulatory effect, which appeared to be mediated
by direct contact with target cells [32]. Foxp3-expressing
CD8+/CD28- Tregs share developmental and phenotypic
features (CD122+/GITR+/CTLA4+/CCR7+/CD62L+/
CD25+/CD127-/IL-23R-) with naturally occurring CD4+
Tregs. Secretion of IL-10 and transforming growth factor
(TGF)-b1 is higher in CD8+/CD25hi/CD28-/Foxp3 Tregs
than in CD8+/CD25hi/CD28- T cells. In addition, Foxp3-
expressing CD8+ Tregs reduce T cell proliferation in
response to a specific antigen and secretion of both IFN-
g and IL-17 by CD4 T cells only through cell-cell contact.
On the other hand, CD8+ Tregs downregulate the co-sti-
mulatory molecule expression on DCs (CD40, CD80,
CD86, MHC I, HLA-DR), inducing a less efficient antigen
presentation [32,34,35]. It has previously been demon-
strated that CD8+/CD28-/Foxp3+ regulatory T cells can
condition DCs to express functional and suppressive IDO
activity [32]. In turn, IDO-expressing pDCs have the
capacity to suppress T-cell responses to allo- and auto-
antigens [36]. In this study, an increase in the percentage
of CD123hi/CCR6+/IDO+ pDC was observed in all pSS
patient groups when compared with the peripheral
Figure 3 Percentage of immunoglobulin (Ig) expression on IL-10-producing B peripheral-cell subtype in patients with primary
Sjögren’s syndrome (pSS). CD19+ blood B cells were obtained by positive selection with microbeads. (A) Representative unstained and
permeabilized sample of peripheral blood mononuclear cells (autofluorescence control). (B) phycoerythrin (PE)-labeled-anti rat-IL-10 IgG isotype
control. (C-E) IgG1-fluorescein isothiocyanate (FITC)/IgG1-PE/CD45-PeCy5 mouse IgG1, k isotype controls (BD Tritest™, BD Biosciences). (F)
Representative contour plot of CD19+ B cells. An electronic gate was made for CD38hi cells. (G) From the gate F CD19+⁄CD38hi/IgM+ cells were
determined. (H) From the latter CD19+⁄CD38hi⁄IgM+⁄IL-10+ cells were defined. A total of 50,000 to 100,000 events were recorded for each sample
before any gate setting, and were analyzed with the CellQuestPro software (BD Biosciences). Bar graphs show percentage of (I) CD19+⁄CD38hi⁄IgM
+⁄IL-10+ (J) CD19+⁄CD38hi⁄IgG+⁄IL-10+, and (K) CD19+⁄CD38hi⁄IgA+⁄IL-10+ cells. (I-K) Results are expressed as median, 10th, 25th, 75th, and 90th
percentiles. *P < 0.05. APC, allophycocyanine.
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frequency observed in healthy subjects. The role of IDO
and the specific IDO-expressing cells in normal and dis-
ease conditions has not yet been fully characterized.
CD123hi/CCR6+/IDO+ pDC constitute only 0.2 to 0.8%
of peripheral blood cells and represent a unique, rather
plastic, versatile, and important immune cell population
capable of producing over 95% of IFN-I synthesized by
PBMC in response to virus and nucleic acid-containing
complexes from the host [37]. In fact, IFN-I upregulation
has been shown in both peripheral cells and salivary
glands from pSS patients, the so-called IFN signature
[38], and it has been postulated that a primary viral infec-
tion induces IFN-I synthesis in salivary glands with
subsequent activation of the adaptive immune response
resulting in autoantibody production against RNA bind-
ing proteins, for example, SSA, SSB, RNP, which are
interferogenic complexes that stimulate CD123hi/CCR6+/
IDO+ cells to synthesize IFN-I, although this does not
distinguish clinical disease activity. Thus, DCs could play
a dual role in pSS pathogenesis: regulation of the
immune response and IFN-I production.
In addition to several Tregs and DCregs, our results
show that human peripheral blood has at least one
more tolerogenic subset, namely IL-10-secreting B cells.
Mauri and colleagues have defined these latter cells as a
regulatory B-cell pool with many subtypes that display a
Figure 4 Percentage of immature/transitional IL-10-producing B peripheral-cell subtype in patients with primary Sjögren’s syndrome
(pSS). CD19+ blood B cells were obtained by positive selection with microbeads. (A) Representative contour plot of CD19+ B cells. An electronic
gate was made for CD38hi cells. (B) From the gate A CD19+⁄CD38hi⁄CD24hi cells were determined. (C) From the gate B CD19+⁄CD38hi⁄CD24hi⁄CD20+
were defined. (D) From the latter CD19+⁄CD38hi⁄CD24hi⁄CD20+⁄IL-10+ cells were determined. Bar graphs show percentage of (E) CD19+⁄CD38hi⁄CD24hi⁄
CD5+⁄IL-10+, (F) CD19+⁄CD38hi⁄CD24hi⁄CD10+⁄IL-10+, (G) CD19+⁄CD38hi⁄CD24hi⁄CD20+⁄IL-10+, (H) CD19+⁄CD38hi⁄CD24hi⁄CD27-⁄IL-10+, (I) CD19+⁄CD38hi⁄
CD24hi⁄CXCR4+⁄IL-10+-, and (J) CD19+⁄CD38hi⁄CD24hi⁄CXCR7+⁄IL-10+-producing B peripheral cells. A total of 50,000 to 100,000 events were recorded
for each sample before any gate setting and were analyzed with the CellQuestPro software (BD Biosciences). (E-J) Results are expressed as median,
10th, 25th, 75th, and 90th percentiles. *P < 0.05.
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CD19+/CD24hi/CD38hi/IL-10+ phenotype [31]. Iwatta
et al. previously reported that CD19+/CD24hi/CD38hi/
CD27+/IL-10+ B10-cell frequencies in blood from a
group of patients with autoimmune diseases, such as
lupus, rheumatoid arthritis, SS, autoimmune skin dis-
ease, and multiple sclerosis, were not significantly differ-
ent from those observed in healthy controls, although
mean B10 and B10 pro-cell frequencies were signifi-
cantly increased. However no further characterization
for each disease was provided [39].
Herein, the regulatory B-cell subset percentage showed
clear differences in pSS patients with active versus inac-
tive disease. CD19+/CD24hi/CD38hi/IL-10+ cells were sig-
nificantly higher in the whole pSS group compared to
HD. However, this difference was at the expense of pSS
patients with clinically inactive disease, where IgA-
expressing regulatory B cells have higher peripheral fre-
quency. IgA secretion by the salivary gland in pSS
patients suggests that its peripheral blood occurrence is a
clear systemic reflection of what might be happening at
the site of injury. Our suggestion is based on work by
Cerutti’s group who have clearly shown that functional
toll-like receptor (TLR)3 is expressed by human tonsillar
B-cells, with higher expression in GCs and sub-epithelial
regions, but is absent from memory B cells (CD27+ cells).
In the presence of dsRNA, these mucosal B cells upregu-
late AID expression and initiate class switch recombina-
tion and IgG/IgA production in the presence of IL-10
and B cell activating factor (BAFF) [40]. Surprisingly,
IgG-expressing regulatory B cells had lower peripheral
Figure 5 Percentage of indoleamine 2,3-dioxygenase (IDO)- and Foxp3-expressing peripheral blood cells in patients with primary
Sjögren’s syndrome (pSS). (A,B) Control of fluorescein isothiocyanate (FITC)-labeled-rabbit anti-sheep specificity staining. (C) An electronic gate
was made for CCR6+ cells. (D) From the gate C CCR6+⁄CD123hi cells were determined. (E) From the latter CCR6+⁄CD123hi⁄IDO+ cells were defined.
(F) An electronic gate was made for CD4+ cells. (G) From the gate F CD4+⁄CD25hi were determined and an electronic gate was made for double
positive cells. (H) From the latter CD4+⁄CD25hi⁄Foxp3+ cells were defined. Bar graphs show percentage of (I) CCR6+⁄CD123hi⁄IDO+ cells, (J) CD4+⁄
CD25hi⁄Foxp3+ cells, (K) CD8+⁄CD28-⁄Foxp3+ cells. A total of 100,000 to 250,000 events were recorded for each sample before any gate setting,
and were analyzed with the CellQuestPro software (BD Biosciences). (I-K) Results are expressed as median, 10th, 25th, 75th, and 90th percentiles.
*P < 0.05.
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frequency in patients compared to healthy individuals.
The lowest frequency was found in pSS patients with
clinically active versus inactive disease. There was no dif-
ference between patients and controls in surface IgM
expression.
Recently, a CD19+/CD24hi/CD38hi/CD5hi B-cell sub-
type has been described. CD5 itself has been demon-
strated to affect B-cell function by negative regulation of
B-cell receptor (BCR) signaling, as well as by inducing
the production of IL-10 [41]. CD5+ IL-10-producing B
cells suppress the proliferation of Th1 through CD40
engagement, and STAT3 phosphorylation. Meanwhile,
the differentiation of Th1 cells is inhibited in an IL-10-
dependent, but TGF-b1-independent manner, which
requires CD80/CD86 interactions with target CD4+
T-cells. In addition to halting Th1 but not Th17
responses, the suppressive effects are mediated by an
indirect mechanism, through the induction of Foxp3+
expression in CD4+/CD25hi T cells [4,9] in a more efficient
way than any other population of antigen-presenting cells
[5,6]. The resulting Tregs displayed a greater suppressive
capacity than regulatory T-cells generated by immature
DCs from the same donor [7]. This suggests that B cell-
dependent suppressive effects are associated with the gen-
eration of Foxp3-expressing CD4+/CD25hi Tregs. In our
study we found higher proportions of CD19+/CD24hi/
CD38hi/CD5+ IL-10-secreting B cells in pSS patients with
clinically inactive disease compared to those with clinically
active disease, the whole pSS group, and healthy controls,
suggesting that CD5+ IL-10-producing B cells are able to
downregulate autoimmune inflammation to induce home-
ostasis [5-8].
Another B cell subpopulation in our patients was that
of CD19+/CD38hi/CD24hi/CD10+/IL-10+ cells. CD10 is a
cell membrane metallopeptidase expressed by early B,
pro-B, and pre-B lymphocytes and diffuse large B cells.
CD10 expression is a well-accepted marker for most of
the transitional T1/T2 B-cell pool, suggesting that these
cells are recent emigrants from the bone marrow [4].
Our findings show a statistically significant increase in
the frequency of these B cells in pSS patients with clini-
cally inactive, serologically inactive, and clinically and
serologically inactive disease compared to pSS patients
with clinically active, serologically active, and clinically
and serologically active disease, and healthy controls,
attributable to a more immature differentiation stage of
these cells (probably T2) [42].
The levels of the CD19+/CD38hi/CD24hi/CD20+/IL-10+
B-cell subset were higher in the whole pSS group, and in
patients with clinically inactive, and clinically and serologi-
cally inactive disease compared to healthy controls. More-
over, levels of CD20+/IL-10+ B cells were significantly
lower in pSS patients with clinically active versus clinically
inactive disease. CD20 is a 33-kd phosphoprotein similar
to an ion channel that allows calcium influx for cell activa-
tion. It is expressed on pre-B and mature B cells after
CD19/CD10 expression, and before CD21/CD22 and sur-
face Ig expression. It is retained on mature B cells until
plasma cell development (plasmablasts) [5]. It has a central
role in the generation of T cell-independent (TI) antibody
responses. Although antigen-independent B cells have
been shown to develop normally, in the absence of CD20
expression, antibody formation, particularly after vaccina-
tion with TI antigens, is strongly impaired in deficient
patients [43]. In this sense, we suggest that the decrease
in CD20 expression in patients with active pSS could be
an immune regulatory mechanism that is able to avoid
autoimmune antibody response and maintain the IL-10-
producing B cell tolerant phenotype.
In addition to the human CD19+/CD24hi/CD38hi-cir-
culating B-cell subpopulation aforementioned, it has
been suggested that CD19+/CD38hi/CD24hi/CD27+/IL-
10+ or B10 cells might be a different Breg subset, as
described by Tedder and colleagues [39]. They are pre-
sent in the splenic marginal zone rather than memory
cells generated in germinal centers. Whereas CD40/
CpG-stimulated B10 cells induce proliferation and pro-
duce higher levels of IL-10 (10-fold) compared to CD27-
(cells that had not yet entered the germinal center), only
B10 cells inhibit mitogen-induced TNF-a production by
monocytes, through IL-10 synthesis [39,44-48], suggest-
ing neither a non-inflammatory nor a viral infectious
process.
Remarkably, when compared to healthy controls, there
were higher levels of naïve and transitional CD19+/
CD38hi/CD24hi/CD27-/IL-10+ B cells in all pSS patient
groups except for the group with clinically active and sero-
logically inactive disease. We consider that the relative
increase in CD27- peripheral B cells could be originated by
a B-cell exhaustion mechanism, where accumulation of
peripheral blood CD27- tissue-like B cells is a consequence
of persistent chronic immune activation (autoimmune dis-
ease) or persistent viral infections. The features of CD27-
B cells include increased expression of multiple inhibitory
receptors, decreased cell function, and poor proliferative
and effector responses to a variety of stimuli [49].
Among all chemokine receptors, CXCR4 induces pro-
longed activation of intracellular signal transduction path-
ways, such as the mitogen-activated protein kinase
(MAPK) cascade. This may elicit anti-apoptotic responses
and thus, contribute to cell survival. In B-cell lymphopoi-
esis, CXCR4/CXCL12 are critical for bone marrow reten-
tion and maturation of the cells [50]. In the present study,
there were no differences between CD19+/CD38hi/
CD24hi/CXCR4+/IL-10+ levels in pSS patients and con-
trols, suggesting that, at least at systemic level, these
cells are not affected by clinical or serologic pSS activity:
CD19+/CD38hi/CD24hi/CXCR7+/IL-10+ regulatory B cells
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were increased in pSS patients with clinically inactive dis-
ease compared to patients with clinically active disease
and healthy controls. CXCR7 is a receptor for chemokines
CXCL12/SDF1 and CXCL11. It does not elicit classical
chemokine receptor signaling; chemokine binding does
not activate G-protein-mediated signal transduction, but
instead induces beta-arrestin recruitment, leading to
ligand internalization and activation of the MAPK signal-
ing pathway. The CXCR7 receptor acts as a scavenger for
CXCL12/SDF1 and, to a lesser extent, for CXCL11. It is
required for regulation of CXCR4 protein levels in migrat-
ing interneurons, thereby adapting their chemokine
responsiveness. CXCR7 promotes cell growth and survival.
It is not involved in cell migration, adhesion or prolifera-
tion of normal hematopoietic progenitors [51,52]. Thus,
we suggest that CXCR7 promotes survival of IL-10-produ-
cing B cells, and CXCR4 could participate in migrating
cells to the site of inflammation, and may perhaps interact
in situ with pro-inflammatory cells.
Clinical disease activity necessarily implies the presence
of an exacerbation trigger (still unknown) that might over-
come the regulatory B effect by the increase of pathogenic
B cells with a concomitant decrease of regulatory B cells.
This certainly leads to an uncontrolled autoimmune pro-
cess and loss of homeostasis. B-cell modulation is clearly a
promising therapy in SS. For instance, rituximab (anti-
CD20 monoclonal antibody) has been employed for the
treatment of extraglandular manifestations, features of SS,
and fatigue in pSS with controversial results in controlled
clinical trials [53]. It eliminates almost all peripheral B
cells, again supporting the notion that B cells are the pre-
ponderant cells at play in pSS pathogenesis. In the same
vein, BAFF is a cytokine clearly implicated in the patho-
genesis of SS. Recently, results of a first open, phase 2
study of belimumab, a monoclonal anti-BAFF antibody,
showed an improvement in clinical activity assessed by the
ESSDAI and ESSPRI indexes [54]. Caution should be
taken, because in theory both drugs may also affect the
Breg cells and could exacerbate inflammation and
autoimmunity.
There are potential limitations to the current study.
First, as expected, the group with clinically active disease
received steroids and immunosuppressors more frequently
(although overall, the latter were not statistically signifi-
cant when compared to the group with clinically inactive
disease); whether or not the impact of the treatment influ-
ences the function of regulatory cells is matter of debate.
However, we consider that our results are still valid and
robust because in the same vein, rheumatoid arthritis
patients with inactive disease have also been recently
reported as having an increased number of CD19+
CD24hiCD38hi B cells compared with patients with active
disease [55]. Second, this work was a cross-sectional study.
Thus, longitudinal studies may be necessary for a better
understanding of causality.
Nevertheless, as far as we know, this is the first study
that evaluated the presence of three regulatory cell sub-
populations, particularly, IL-10-producing B cells in pSS
patients. Undoubtedly, the immunobiology of regulatory
B cells is still young and much remains to be learned
about regulatory mechanisms. Next, evaluation should
consider exploring ontogeny and population diversity,
differentiation pathways, transcription factor(s), specific
surface markers, plasticity and functionality of the cells
involved. Our preliminary results deserve to be studied
in depth to appraise the clinical relevance of these find-
ings. In this vein, the evaluation of these cells in salivary
glands is ongoing, to confirm peripheral blood findings,
and certainly functional studies will be needed.
Conclusion
In general it can be concluded that the levels of regula-
tory B-cell phenotypes studied were greater in patients
with clinically inactive pSS and serologically inactive
pSS. These findings emphasize two important Breg
functions: the control of autoimmune disease and
restoration of immune homeostasis. Moreover, Breg
immunophenotyping appears to be a reliable marker of
cell stability and control of the disease, which may be
useful for monitoring those patients who progress to
lymphoma.
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